12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Egrifta tesamorelin regulatory update

Theratechnologies said it and partner Actelion Ltd. (SIX:ATLN, Allschwil, Switzerland) responded to questions contained in a notice of non-compliance from Health Canada for an NDS for tesamorelin to treat excess abdominal fat in HIV-infected patients with lipodystrophy. The notice contained questions on...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >